Hepatic failure. Hepatic failure, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: Patients receiving high doses of statins who have increased levels of aminotransferases (ALT or AST) equal to or more than 1.5 times and less than 3 times the upper
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients receiving high doses of statins (Atorvastatin with a dose of more than 40 mg or Rosuvastatin with a dose of more than 20 mg) Abnormalities in liver function tests (increased aminotransferase level equal to or more than 1.5 and less than 3 times the upper limit of the normal range) Consent to admission to the study No previous medical history of liver disease or elevated aminotransferase before statin initiation
Exclusion criteria
Exclusion criteria: Receiving other drugs that may affect the increase of liver enzymes Elevation of LFT equal to or greater than 3 times
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in ALT levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in AST levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in CBC diff. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in lipid profile levels. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit.;Changes in hs-CRP serum level. Timepoint: At the beginning of the study and after 8 weeks of treatment. Method of measurement: Laboratory kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Vafa Baradaran Rahimi
Mashhad University of Medical Sciences
Outcome results
None listed